Silence Therapeutics closes $201M public offering of ADSs

Silence Therapeutics plc (NASDAQ: SLN) closed an underwritten public offering of 14,907,407 American Depositary Shares (ADSs) at $13.50 per ADS, according to a press release statement.

The total includes the full exercise by underwriters of their option to purchase an additional 1,944,444 ADSs. Gross proceeds from the offering reached approximately $201.3 million, before deducting underwriting discounts, commissions, and other offering expenses.

Each ADS represents three ordinary shares of £0.05 each in the capital of the company. Jefferies, Morgan Stanley, Cantor, and William Blair acted as joint book-running managers for the offering.

A shelf registration statement related to the offering was filed with the U.S. Securities and Exchange Commission on May 18, 2026, and declared effective on May 27, 2026.

You May Also Be Interested In

• Gossamer Bio raises up to $250M in private placement for PAH drug
• Singularity Future Technology prices $5M direct offering at $3.20 per share
• Andersen prices secondary offering of 4.28M shares at $44 each